olmesartan (benicar) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Oral olmesartan medoxomil 10-40 mg once daily is recommended for the treatment of adult patients with hypertension, this dosage has consistently helped achieve a double-digit reduction both in systolic and diastolic blood pressure, a reduction which is maintained for one year. Extensive clinical evidence from several large well designed trials and the clinical practice setting has confirmed the antihypertensive efficacy and good tolerability profile of oral olmesartan medoxomil, as monotherapy in patients with hypertension. Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide). Adverse events were infrequent in clinical studies of olmesartan medoxomil and were similar to those attributed to placebo.   NCATS

Chemistry

  • SMILES: CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=NN4)C(O)=O)C(C)(C)O
  • InChIKey: VTRAEEWXHOVJFV-UHFFFAOYSA-N
  • Mol. Mass: 446.5016
  • ALogP: 4.17
  • ChEMBL Molecules:
    olmesartan medoxomil  
    olmesartan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.0799 - $10.7502

Australia

$0.1096 - $0.3166
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( amlodipine (norvasc), olmesartan (benicar) - other name: amlodipine and olmesartan medoxomil )
|
( olmesartan (benicar), hydrochlorothiazide (esidrix) )
|
( amlodipine (norvasc), olmesartan (benicar), hydrochlorothiazide (esidrix) - other name: olmesartan medoxomil, amlodipine and hydrochlorothiazide )

Alternative names

4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid | 4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylic acid | 4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid | benicar | cs-088 | cs866 | cs-866 | olmesartaan medoxomil | olmesartan | olmesartan medoxomil | olmetec | omesartan | rnh 6270 | rnh-6270 | sevikar

Organizations (136)

Research & Development (109)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (36)

Approved Indications (5)


 

Diabetes Mellitus

Heart Failure

Hypertension

Myocardial Infarction

Stroke

Experimental Indications - Clinical Trial Phases 1-4 (34)


 

Arrhythmias, Cardiac (Phase 3)

Atherosclerosis (Phase 3)

Atrial Fibrillation (Phase 3)

Brain Diseases (Phase 3)

Cardiomyopathy, Dilated (Phase 4)

Cardiomyopathy, Hypertrophic (Phase 1)

Cardiovascular Diseases (Phase 4)

Carotid Artery Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 3)

Dyslipidemias (Phase 4)

Essential Hypertension (Phase 4)

Glomerulonephritis (Phase 2)

Glomerulonephritis, IGA (Phase 4)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 3)

Heart Failure (Phase 3)

Hyperlipidemias (Phase 3)

Hypertension ()

Insulin Resistance (Phase 4)

Ischemic Stroke (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 4)

Metabolic Syndrome (Phase 4)

Obesity (Phase 4)

Overweight (Phase 4)

Peripheral Arterial Disease (Phase 4)

Prehypertension (Phase 4)

Proteinuria (Phase 3)

Safety (Phase 3)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 127
  • # of Trial Organizations: 109

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue